Selinexor - Karyopharm Therapeutics

Drug Profile

Selinexor - Karyopharm Therapeutics

Alternative Names: CRM1-nuclear-export-inhibitor; KPT-330

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Barbara Ann Karmanos Cancer Institute; Cardiff University; Dana-Farber Cancer Institute; Erasmus MC; H. Lee Moffitt Cancer Center and Research Institute; Karyopharm Therapeutics; Lymphoma Academic Research Organisation; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National University Hospital (Singapore); Rigshospitalet; Sheba Medical Center; St. Jude Childrens Research Hospital; The Ohio State University Comprehensive Cancer Center; University Health Network; University of Chicago; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Weill Cornell Medical College
  • Class Acrylamides; Antineoplastics; Hydrazines; Pyrazines; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Liposarcoma; Multiple myeloma
  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Glioblastoma; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Small cell lung cancer; Squamous cell cancer; Thymoma
  • Phase I/II Chronic myelomonocytic leukaemia; Non-Hodgkin's lymphoma; Soft tissue sarcoma
  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Diabetic foot ulcer; Gastric cancer; Malignant melanoma; Oesophageal cancer; Osteosarcoma; Rectal cancer; Solid tumours
  • Preclinical Myelofibrosis; Non-small cell lung cancer

Most Recent Events

  • 10 Dec 2017 Additional efficacy data from the phase I/II trial STOMP trial in Multiple myeloma released by Karyopharm Therapeutics
  • 09 Dec 2017 Adverse events and efficacy data from the phase Ib/II STOMP trial in Multiple myeloma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 09 Dec 2017 Efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top